GT BiopharmaGTBP
13F holders, Q1 2024 (March 31)16holders
$4.62avg. 13F price*
At the end of Q1 2024, 16 institutions reported holding GT Biopharma Inc. (GTBP) in their 13F filings. The largest holders were Bank of Montreal ($102K), Vanguard Group Inc. ($91K) and Geode Capital Management, LLC ($50K).
- Company
- GT Biopharma Inc.
- CUSIP
- 36254L308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $298 |
| Exits | 1 | $38 |
Ownership 16 holders
| Bank of Montreal | 0.00% | No change | 19,872 | $102K |
| Vanguard Group Inc. | 0.00% | Reduce -43.4% | 20,512 | $91K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.5% | 11,184 | $50K |
| BlackRock Inc. | 0.00% | No change | 10,132 | $45K |
| Wells Fargo & Company | 0.00% | No change | 10,024 | $44K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +249.1% | 2,301 | $10K |
| UBS Group AG | 0.00% | Add +110.1% | 1,023 | $5K |
| Morgan Stanley | 0.00% | Reduce -1.2% | 266 | $1K |
| FMR LLC | 0.00% | New | 61 | $271 |
| Osaic Holdings, Inc. | 0.00% | Reduce -5.6% | 32 | $142 |
| Bank of America Corp. | 0.00% | Reduce -52.5% | 17 | $75 |
| Blue Bell Private Wealth Management, LLC | 0.00% | No change | 10 | $44 |
| BNP Paribas Financial Markets | 0.00% | New | 6 | $27 |
| JPMorgan Chase & Co. | 0.00% | Add +87.5% | 1 | $4 |
| Front Row Advisors LLC | 0.00% | Reduce -98.3% | 1 | $4 |
| Royal Bank of Canada | 0.00% | Reduce -90.4% | 7 | $0 |
"% of holder's portfolio" is GTBP's weight in each manager's 13F, not the share of GT Biopharma Inc. the manager owns.